Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Recent developments in artificial intelligence (AI) have introduced new technologies that can aid in detecting cognitive decline. This study developed a voice-based AI model that screens for cognitive decline using only a short conversational voice sample. The process involved collecting voice samples, applying machine learning (ML), and confirming accuracy through test data. The AI model extracts multiple voice features from the collected voice data to detect potential signs of cognitive impairment. Data labeling for ML was based on Mini-Mental State Examination scores: scores of 23 or lower were labeled as "cognitively declined (CD)," while scores above 24 were labeled as "cognitively normal (CN)." A fully coupled neural network architecture was employed for deep learning, using voice samples from 263 patients. Twenty voice samples, each comprising a one-minute conversation, were used for accuracy evaluation. The developed AI model achieved an accuracy of 0.950 in discriminating between CD and CN individuals, with a sensitivity of 0.875, specificity of 1.000, and an average area under the curve of 0.990. This voice AI model shows promise as a cognitive screening tool accessible via mobile devices, requiring no specialized environments or equipment, and can help detect CD, offering individuals the opportunity to seek medical attention.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129157PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0325177PLOS

Publication Analysis

Top Keywords

cognitive decline
12
voice samples
12
voice
8
detecting cognitive
8
labeled "cognitively
8
cognitive
5
utility artificial
4
artificial intelligence-based
4
intelligence-based conversation
4
conversation voice
4

Similar Publications

BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder. While AD diagnosis traditionally relies on clinical criteria, recent trends favor a precise biological definition. Existing biomarkers efficiently detect AD pathology but inadequately reflect the extent of cognitive impairment or disease heterogeneity.

View Article and Find Full Text PDF

BackgroundTherapeutic plasma exchange (TPE) with albumin replacement has emerged as a potential treatment for Alzheimer's disease (AD). The AMBAR trial showed that TPE could slow cognitive and functional decline, along with changes in core and inflammatory biomarkers in cerebrospinal fluid.ObjectiveTo evaluate the safety and effectiveness of TPE in a real-world setting in Argentina.

View Article and Find Full Text PDF

Introduction: Cognitive frailty (CF), which typically precedes dementia and functional decline, serves as a more robust predictor of adverse health outcomes compared to physical frailty alone, representing a critical challenge in promoting healthy aging among older people living with HIV (PLWH) aged ≥ 50 years. This study aimed to investigate the prevalence of cognitive frailty and identify its associated factors among PLWH aged ≥ 50 years.

Methods: A convenience sample of 344 PLWH ≥ 50 years was recruited from a tertiary Grade A hospital in Zunyi, China.

View Article and Find Full Text PDF

Cerebellar Stimulation Modulates Reward Processing: A High-definition Transcranial Direct Current Stimulation Study.

Cerebellum

September 2025

Neuropsychology and Applied Cognitive Neuroscience Laboratory, State Key Laboratory of Cognitive Science and Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.

Reward processing involves several components, including reward anticipation, cost-effort computation, reward consumption, reward sensitivity, and reward learning. Recent research has highlighted the cerebellum's role in reward processing. This study aimed to investigate the effects of cerebellar stimulation on reward processing using high-definition transcranial direct current stimulation (HD-tDCS).

View Article and Find Full Text PDF

Brain ischemia is a major global cause of disability, frequently leading to psychoneurological issues. This study investigates the effects of 4-aminopyridine (4-AP) on anxiety, cognitive impairment, and potential underlying mechanisms in a mouse model of medial prefrontal cortex (mPFC) ischemia. Mice with mPFC ischemia were treated with normal saline (NS) or different doses of 4-AP (250, 500, and 1000 µg/kg) for 14 consecutive days.

View Article and Find Full Text PDF